Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Veklury Peaks And Leaves Gilead In The Lurch

The Pandemic Still Drags On Other Antiviral Sales

Executive Summary

Veklury rescued Gilead’s weak underlying first-quarter performance. But the pandemic and its associated behavioral effects, as well as patent expiries, will continue to drag. 

You may also be interested in...



Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries

Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.

Stock Watch: Post-Pandemic Life Science Market Dynamics

Factors in addition to the rejuvenation of pharmaceutical revenues and biotechnology product failures are likely to pull in opposite directions at the sector’s recovery from the pandemic.

Stock Watch: Class Of 2016 FDA Approvals

Revenues are still elusive for a surprising number of the novel drugs approved by the FDA five years ago. Emergent safety issues and confirmatory clinical trial failures were less common than lack of competitiveness as the main reason for revenue weakness.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel